At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Closed 11-13 16:00:00 EST
360.45
-12.33
-3.31%
High372.87Low360.13Vol18.11M
Open372.69D1 Closing372.78Amplitude3.42%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O245.93MT/O Rate--Tradable Shares0.00
P/B2.722295ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)
TIPRANKS  ·  04:10
Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)
Positive Trial Data Might Change The Case For CRISPR Therapeutics Stock
Simply Wall St.  ·  11-13 17:28
Positive Trial Data Might Change The Case For CRISPR Therapeutics Stock
Alpha Cognition Appoints Caren Deardorf to Board
Reuters  ·  11-13 05:41
Alpha Cognition Appoints Caren Deardorf to Board
CRISPR Therapeutics Advances Gene-Editing Trial for High Blood Pressure
TIPRANKS  ·  11-13 00:33
CRISPR Therapeutics Advances Gene-Editing Trial for High Blood Pressure
Intellia's Lonvo-Z Cuts HAE Attack Rate 81% Versus Prior Prophylaxis in Phase 3 Trial
Reuters  ·  11-12 23:09
Intellia's Lonvo-Z Cuts HAE Attack Rate 81% Versus Prior Prophylaxis in Phase 3 Trial
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
GlobeNewswire  ·  11-12 23:00
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
Century Therapeutics Q3 Net Loss Narrows, Beats Analyst Expectations
Reuters  ·  11-12 20:14
Century Therapeutics Q3 Net Loss Narrows, Beats Analyst Expectations
TScan Therapeutics Q3 Revenue Drops After Amgen Collaboration Ends
Reuters  ·  11-12 20:08
TScan Therapeutics Q3 Revenue Drops After Amgen Collaboration Ends
Switzerland's Pharvaris Q3 Loss Widens as Costs Rise
Reuters  ·  11-12 20:07
Switzerland's Pharvaris Q3 Loss Widens as Costs Rise
Does Pivotal Sickle Cell Trial Success Change The Bull Case For Beam Therapeutics (BEAM)?
Simply Wall St.  ·  11-12 16:31
Does Pivotal Sickle Cell Trial Success Change The Bull Case For Beam Therapeutics (BEAM)?
CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value
Simply Wall St.  ·  11-12 16:25
CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
TIPRANKS  ·  11-11 21:36
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)
TIPRANKS  ·  11-11 18:40
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)
Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain
Simply Wall St.  ·  11-11 16:27
Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain
Beam Therapeutics (BEAM) Dropped, So What Is Behind The Latest Attention?
Simply Wall St.  ·  11-11 14:29
Beam Therapeutics (BEAM) Dropped, So What Is Behind The Latest Attention?
Atara Biotherapeutics Q3 Revenue Beats Estimates as Costs Decline
Reuters  ·  11-11
Atara Biotherapeutics Q3 Revenue Beats Estimates as Costs Decline
Analysts’ Top Healthcare Picks: Tecan Group AG (TCHBF), Beam Therapeutics (BEAM)
TIPRANKS  ·  11-11
Analysts’ Top Healthcare Picks: Tecan Group AG (TCHBF), Beam Therapeutics (BEAM)
Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint
TIPRANKS  ·  11-11
Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint
Editas Medicine Presents EDIT-401 Data Showing over 90% Mean LDL-C Reduction in Nonhuman Primates
Reuters  ·  11-10
Editas Medicine Presents EDIT-401 Data Showing over 90% Mean LDL-C Reduction in Nonhuman Primates
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
GlobeNewswire  ·  11-10
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--